Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.48 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30274560 | 1.00 | KDM4E (0.54) | KDM4ELMNAHTTHSD17B10CCNC | |
| SCHEMBL15483262 | 0.94 | CCNC (0.52) | KDM4ELMNAHTTHSD17B10CCNC | |
| SCHEMBL8541628 | 0.89 | FERMT2 (0.57) | KDM4ELMNAHTTHSD17B10CCNC | |
| SCHEMBL2328345 | 0.88 | FERMT2 (0.51) | KDM4ELMNAHTTHSD17B10CCNC | |
| SCHEMBL14482022 | 0.81 | FERMT2 (0.53) | KDM4ELMNAHTTHSD17B10CCNC | |
| SCHEMBL21687782 | 0.80 | CLK4 (0.44) | KDM4ELMNAHTTHSD17B10CCNC | |
| SCHEMBL1861045 | 0.80 | CCNC (0.55) | CCNCCDK8FERMT2HTR1AADRA1D | |
| SCHEMBL5549300 | 0.80 | FERMT2 (0.68) | CCNCCDK8FERMT2HTR1AADRA1D | |
| SCHEMBL1855953 | 0.80 | CCNC (0.55) | CCNCCDK8FERMT2HTR1AADRA1D | |
| SCHEMBL21643599 | 0.79 | CLK4 (0.46) | CCNCCDK8FERMT2HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | SIXFOLD BIOSCIENCE LTD (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2022-06-14 | — | — | US | disclosed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | disclosed |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357865-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | KDM4E 3992/4885LMNA 514/4885HTT 459/4885 |
| US-20220370635-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | KDM4E 3992/4885LMNA 514/4885HTT 459/4885 |
| US-20210330810-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | NCL, NSUN3, POLN | KDM4E 3992/4885LMNA 514/4885HTT 459/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | KDM4E 3992/4885LMNA 514/4885HTT 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.